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Background: Health-policy decision making is a complex and dynamic process, for which strong evidentiary support is
required. This includes scientifically produced research, as well as information that relates to the context in which the
decision takes place. Unlike scientific evidence, this “contextual evidence” is highly variable and often includes
information that is not scientifically produced, drawn from sources such as political judgement, program management
experience and knowledge, or public values. As the policy decision-making process is variable and difficult to evaluate,
it is often unclear how this heterogeneous evidence is identified and incorporated into “evidence-based policy”
decisions. Population-based colorectal cancer screening poses an ideal context in which to examine these issues. In
Canada, colorectal cancer screening programs have been established in several provinces over the past five years,
based on the fecal occult blood test (FOBT) or the fecal immunochemical test. However, as these programs develop,
new scientific evidence for screening continues to emerge. Recently published randomized controlled trials suggest
that the use of flexible sigmoidoscopy for population-based screening may pose a greater reduction in mortality than
the FOBT. This raises the important question of how policy makers will address this evidence, given that screening
programs are being established or are already in place. This study will examine these issues prospectively and will focus
on how policy makers monitor emerging scientific evidence and how both scientific and contextual evidence are
identified and applied for decisions about health system improvement.
Methods: This study will employ a prospective multiple case study design, involving participants from Ontario, Alberta,
Manitoba, Nova Scotia, and Quebec. In each province, data will be collected via document analysis and key informant
interviews. Documents will include policy briefs, reports, meeting minutes, media releases, and correspondence.
Interviews will be conducted in person with senior administrative leaders, government officials, screening experts, and
high-level cancer system stakeholders.
Discussion: The proposed study comprises the third and final phase of an Emerging Team grant to address the
challenges of health-policy decision making and colorectal cancer screening decisions in Canada. This study will
contribute a unique prospective look at how policy makers address new, emerging scientific evidence in several
different policy environments and at different stages of program planning and implementation. Findings will provide
important insight into the various approaches that are or should be used to monitor emerging evidence, the relative
importance of scientific versus contextual evidence for decision making, and the tools and processes that may be
important to support challenging health-policy decisions.
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Health-policy decision making poses many challenges. There
is an unprecedented proliferation of scientific information
available to policy makers, and with it, increasing demand
to ensure that decisions are based on the highest-quality
up-to-date evidence [1]. Similar challenges in clinical prac-
tice have resulted in strong emphasis being placed on evi-
dence-based medicine, a linear process of decision making
in which scientific evidence is applied to resolve identified
“knowledge gaps” [2]. Increasingly, the concept of evidence-
based decision making is applied to health policy and is fre-
quently cited as a political or tactical tool to suggest an ap-
proach that results in higher-quality policy decisions [1].
However, while the application of evidence-based medicine
to resolve clinical questions is widely accepted, “evidence-
based health policy” (EBHP) is far less clear [1-3].
Unlike clinical decisions, policy decisions are inherently
context-specific [1,2] and require a diverse array of evidence
and stakeholder involvement at various stages of the deci-
sion-making process [1,2]. Those who participate in health-
policy decision making may range from senior government
and administrative officials, trained methodologists and clini-
cians, program managers, or community stakeholders [1].
These actors are “anchored within institutional settings” and
often have diverse perspectives and interpretations of rele-
vant evidence [1,4]. In a report by Lomas et al., the hetero-
geneity of evidence used for health-policy decision making
was characterized as “scientific context-free,” “scientific con-
text-sensitive,” and “colloquial” [5]. In this typology, an im-
portant distinction is drawn between evidence generated via
scientific methods that describes what works under ideal cir-
cumstances, scientific evidence that refers to a specific con-
text, and colloquial evidence that broadly implies “anything
that establishes a fact or gives reason for believing in some-
thing” (i.e., stakeholder opinion and values) [5]. To address
complex policy decisions, policy makers must often “iden-
tify,” “interpret,” and “apply” each of these forms of evidence
in terms of their relevance to the decision at hand [5,6].
However, while scientific and colloquial evidence pertaining
to the local context (hereafter referred to under the broad
heading of “contextual evidence”) play a crucial role in deci-
sion making, this role is often unclear. Unlike non-context-
specific evidence published in scientific journals, contextual
evidence is often harder to define and to obtain. It does not
fit properly within the evidence-based framework and thus
there is a lack of clarity as to how it impacts decision
making.
Finally, unlike clinical decisions, multifactorial policy
decisions are not outlined in clear linear stages [1,2]. In-
stead, they comprise a series of objectives/foci, including
efficacy/effectiveness (will it work), appropriateness/feasi-
bility (should we do it), and implementability (how do we
do it here) [6]. Increasingly there appears to be more focus
on questions related to implementation [6], whichcorresponds to the difficulties policy makers face in allo-
cating resources and planning complex programs. For
challenging implementation-related questions, if context-
ual evidence is ill defined or unavailable, this may result in
program-management approaches dominating evidence-
based approaches when decisions must be made [7]. Ul-
timately, due to the challenges of evaluating the policy de-
cision-making process and the lack of clarity in how
evidence is used, it is often very difficult to identify what is
an EBHP decision or how it was reached.Situating the study
Colorectal cancer (CRC) screening presents an ideal con-
text to examine the challenges of health-policy decision
making. The second most common cause of cancer
deaths in Canada [8], CRC has a well-known path of dis-
ease progression and vastly improved chances of survival
with early diagnosis [9]. However, while there is strong
evidence to support population-based screening, there
are fewer definitive answers as to the characteristics of
the screening program that should be in place and how
to implement them. There are a variety of modalities to
screen for CRC, each of which poses various advantages
and disadvantages for population-based programs. In
Canada, screening decisions have been made in several
provinces based on the implementation of the fecal oc-
cult blood test (FOBT) or fecal immunochemical test
(FIT), yet questions still remain as to the optimal design
of these programs. Meanwhile, new evidence continues
to emerge, bringing renewed perspective to the CRC
screening policy debate. In a recent UK-based trial by
Atkin et al. [10], the use of once-only flexible sigmoidos-
copy (FS) for population-based screening demonstrated a
significant reduction in CRC-related mortality, suggest-
ing even greater population-wide benefit than the
biennial screening with FOBT currently in place in most
provincial programs [11]. This trial is one of four major
randomized controlled trials, including the SCORE [12],
NORCCAP [13], and PLCO [14] trials, that together pro-
vide high-quality evidence of the utility of FS for popula-
tion-based screening. As evidence mounts, policy makers
will need to decide on the relevance of these findings for
the screening programs currently in place.
In examining this subject, the proposed study builds
on previous formative research on the use of evidence to
inform complex cancer-screening policy decisions. From
2002–2006, Dobrow et al. retrospectively examined how
four expert groups in Ontario made screening policy
recommendations for four types of cancer screening
(colorectal, breast, cervical, and prostate) [6]. With the
insight gained from this work, a second retrospective
study was conducted to more closely examine screening
decisions for a single disease site (CRC) across different
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evidence and guidance from advisory bodies, significant
differences among the provinces were observed in terms
of what constituted the ultimate decision to establish
screening, the key questions asked, and how evidence
was used. Preparation of a manuscript of this work is
currently in progress.
This study comprises the final phase of this work and
will examine prospectively how emerging scientific evi-
dence on FS is addressed by policy makers in five pro-
vinces. This study reflects an important progression in
our work, revisiting the same five provinces and provid-
ing a new and innovative perspective in an area in which
relatively little is known—the impact of emerging scien-
tific evidence when policy decisions have already been
made. This issue is timely and relevant in Canada, as
screening programs continue to be developed and
implemented, and the Canadian Partnership Against
Cancer has convened an anticipatory science panel to
examine new evidence on FS [11]. This issue is also of
relevance internationally, given the wide variability in
programs that have been implemented and ongoing
interest in evaluating how these decisions are and con-
tinue to be made [7,15]. This study’s research team is in
a unique position to consider these issues and to provide
findings that are insightful to population-based screen-
ing programs in Canada and elsewhere.
Hypotheses/assumptions
In developing the methodology and rationale for this
study, we incorporate some key assumptions. Primarily,
we assume policy makers use a variety of different
approaches to monitor and identify emerging scientific
evidence and that these approaches will vary based on jur-
isdiction and stakeholder group. We also make the as-
sumption that there are limited formal tools and guidance
to support policy makers in integrating emerging scientific
evidence with relevant contextual information.
We intend to approach policy makers with the ques-
tion of whether to incorporate FS into population-based
programs and hypothetically how this decision should be
made. Consequently, we anticipate that policy makers
will not provide a definitive yes/no response but will dis-
cuss gaps in contextual information that must be filled,
particularly pertaining to program implementation, and
context-specific factors that would determine how this
issue is addressed.
Research questions
Based on the above, this study will address the following
research questions:
1.)How do policy makers monitor and become aware of
emerging scientific evidence?2.)How does new scientific evidence impact established
screening programs/policies?
3.)How do policy makers identify/interpret contextual
evidence?
4.)How does contextual evidence impact established
screening programs/policies?
5.)How do policy makers integrate scientific with
contextual evidence to address decisions about
health system improvement?
Methods/Design
This study will employ a prospective, multiple case study
design involving participants from Ontario, Manitoba,
Alberta, Nova Scotia, and Quebec. Primary methods for
data collection will include document analysis and semi-
structured interviews in each province.
Documents relevant to each province’s consideration
of evidence for CRC-screening decisions will be col-
lected. A systematic search strategy will be used to col-
lect these data, beginning with documents available in
the public domain, followed by requests to key infor-
mants and organizations for further material. Documents
will include policy recommendations/reports/briefs,
planning documents, meeting minutes, media releases,
and correspondence.
Interviews will be conducted with five to eight policy
makers and cancer system stakeholders in each province,
including administrative leaders, government officials,
screening experts, and other high-level stakeholders from
ministries of health and cancer agencies. Purposive sam-
pling will be used to identify these informants, with snow-
ball sampling used subsequently to further identify
individuals involved in CRC-screening decisions for the
province. All potential interviewees will be sent an intro-
ductory package explaining the project and describing pro-
cedures for confidentiality and informed consent. The
research team will then contact the individual by phone
and arrange a convenient interview time. Interviews will
be conducted in person and will last approximately 60
minutes each. Any additional interviews will be conducted
by telephone. All participants will be asked to sign consent
forms prior to the interview. Interviews will be audio-
recorded and transcribed verbatim where permission is
granted. Data will be analyzed using NVivo (QSR Inter-
national, Cambridge, MA, USA) qualitative analysis soft-
ware. For this project, ethical approval has been sought
and obtained from the University of Toronto’s Research
Ethics Board.
This study will be completed in accordance with the time-
line of our Canadian Institutes of Health Services Research
Emerging Team Grant. It is anticipated that the data collec-
tion phase of this work, including document collection and
key informant interviews, will be completed by September
2012, with transcription and coding of the interview data to
Geddie et al. Implementation Science 2012, 7:51 Page 4 of 4
http://www.implementationscience.com/content/7/1/51be completed by the end of the calendar year. Following
this, the analysis and write up of findings will take place and
will be completed by March 31, 2013.Discussion
As scientific evidence continues to emerge, posing new op-
portunities for health system improvement, it is important
to examine how policy makers will respond. Primarily, the
findings of this study will provide insight into how emerging
scientific evidence is monitored, and how this varies across
stakeholder groups and jurisdictions. If key informants are
already aware of emerging evidence on FS and engaging in
steps to address this evidence, study findings will allow for
comparison of what methods and processes are currently
being used. Conversely, if key informants are unaware or
unable to discuss emerging scientific evidence, study find-
ings will provide valuable insight into what methods/pro-
cesses should be in place for this (if any), and how to better
support policy makers in this important area.
Furthermore, this study will provide important insight
into the relative importance of scientific versus context-
ual evidence for decisions about health system change.
Although scientific evidence is disseminated on a contin-
ual basis, evidence appears to be less clear for program
and implementation-related questions that pose signifi-
cant challenges for policy makers. For this, the multiple
case study design is ideal and will allow for comparison
of ways in which contextual evidence is identified and
applied in five unique jurisdictions at various stages of
program planning and implementation.
Finally, in evaluating health-policy decision making, re-
search is often reactive. Instead of examining retrospect-
ively how decisions have been made, this study will
provide unique insight into policy decision making from
a hypothetical and prospective sense. We hope to con-
tribute positively to the EBHP literature and to help sup-
port and advance the use of evidence in making
challenging policy decisions that profoundly impact our
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